Vitamin D Therapy Market Valued to Reach USD $6.05 Billion by 2030 at 13.4% CAGR

The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

How Will the Market Growth Rate of the Vitamin D Therapy Market Impact Future Demand?
The vitamin d therapy market size has grown rapidly in recent years. It will grow from $3.24 billion in 2025 to $3.67 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to rising prevalence of vitamin d deficiency, increased consumer awareness about bone health, expansion of otc vitamin d supplements, growth in geriatric population, adoption of fortified foods and beverages.

The vitamin d therapy market size is expected to see rapid growth in the next few years. It will grow to $6.05 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to advancements in personalized nutrition, integration of vitamin d in functional foods, growth in preventive healthcare, increasing government initiatives for micronutrient supplementation, rise in chronic disease management. Major trends in the forecast period include personalized vitamin d supplementation, fortified food and beverage integration, growing awareness of vitamin d deficiency, increased focus on bone health and immunity, rise in home healthcare solutions.

Claim your free report sample now:
The Business Research Company - Market Research & Business Intelligence

What Are the Key Growth Factors Supporting the Vitamin D Therapy Market Expansion?
An increased prevalence of malnutrition cases is expected to propel the growth of the vitamin D therapy market going forward. Malnutrition refers to deficiencies or excesses in nutrient intake, imbalances of essential nutrients, or impaired nutrient utilization. Vitamin D deficiency is highly prevalent in the population of malnourished inpatients and is negatively associated with long-term mortality, particularly when patients are not receiving vitamin D treatment. Thus, the increased prevalence of malnutrition cases creates demand for vitamin D therapy. For instance, in August 2025, according to UNICEF, a US-based United Nations agency, reported that more than 251.7 million children under 5 were screened for wasting in 64 countries, exceeding the target of 200 million; of these, more than 9.3 million children with severe wasting were admitted for life-saving treatment. Therefore, the increasing prevalence of malnutrition cases is driving the growth of the vitamin D therapy market.

What Are the Key Segment Classifications in the Vitamin D Therapy Market?
The vitamin d therapy market covered in this report is segmented –

1) By Administration: Oral, Parenteral
2) By Purchasing: OTC Drugs, Prescription Drugs
3) By Age Group: Children, Adults, Senior Adults
4) By Application: Osteoporosis, Rickets, Skin Diseases, Muscle Weakness, Autoimmune Disorders

Subsegments:
1) By Oral: Vitamin D3 Supplements (Cholecalciferol), Vitamin D2 Supplements (Ergocalciferol), Vitamin D Fortified Foods And Beverages
2) By Parenteral: Injectable Vitamin D3 (Cholecalciferol), Injectable Vitamin D2 (Ergocalciferol), Intravenous Vitamin D Preparations

Which Trends Are Expected to Redefine the Vitamin D Therapy Market Landscape?
Major companies operating in in the vitamin D therapy market are get into partnerships to strengthen their position in the market. A business strategic partnership refers to a structured affiliation between two or more commercial enterprises, typically established via one or more business agreements or contracts. For instance, in July 2024, Catalyst Pharmaceuticals, Inc. Ltd., a US-based pharmaceutical company entered into a License, Supply, and Commercialization Agreement with Kye Pharmaceuticals Inc, a Canada-based pharmaceutical company, granted Kye the exclusive Canadian commercial rights to AGAMREE (vamorolone). Vamorolone is used to treat Duchenne muscular dystrophy (DMD), due to deficiency of vitamin.

Who Are the Key Players Driving the Vitamin D Therapy Market?
Major companies operating in the vitamin d therapy market are Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Pfizer Inc., Merck & Co Inc., Torrent Pharmaceuticals Ltd., Novartis International AG, Alkem Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd., Biotics Research Corporation, Solvay Pharma India Pvt. Ltd., Forgo Pharmaceuticals Ltd., Mankind Pharmaceuticals Pvt. Ltd., Cipla Ltd., Ortho Molecular Products, Zhejiang Garden Biochemical High-tech Co. Ltd., Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Lupin Ltd., Macleods Pharmaceuticals Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Biocare Medical LLC, Mitsubishi Chemical Group, Zydus Cadila, DSM Nutritional Products AG, BASF SE, Fermenta Biotech Ltd., Taizhou Hisound Pharmaceutical Co. Ltd.

Get the full vitamin d therapy market report here:
https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report

Which regions are expected to experience the fastest growth in the Vitamin D Therapy Market?
North America was the largest region in the vitamin D therapy market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vitamin d therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn